Leah Lawrence

DocwireNews

Among patients with severe <a href="https://www.docwirenews.com/page/hemophilia">hemophilia</a> receiving treatment on demand, annualized joint bleeding rate (AJBR) was associated with free tissue factor pathway inhibitor (fTFPI) levels, and fTFPI affected patients’ thrombin generation (TG) potential, a new study showed.
“The severity of the bleeding phenotype, characterized by a low TG potential, is correlated with the extent of deficiency of the factor concerned,” study researchers explained. “However, the clinical expression of hemophilia in terms of bleeding can vary from one patient to another despite their presenting the same degree of coagulation factor deficiency, suggesting that other factors may play a role.”
In <a href="https://onlinelibrary.wiley.com/doi/10.1111/hae.15020" target="_blank" rel="noopener">this study</a>, the researchers sought to investigate the relationships between bleeding rate and TG potential, TG potential and fTFPI level, and between fTFPI level and bleeding rates. The study included data on bleeding episodes from patients with severe hemophilia A (n=34) or severe hemophilia B (n=19) gathered from follow-up visits that occurred over a period of five to 10 years.
<h2>What Causes Bleeding in Severe Hemophilia?</h2>
Overall, the mean fTFPI level was 12.5 ng/mL. There was no difference in mean fTFPI levels between patients with hemophilia A or hemophilia B (median 10.5 vs 13.3 ng/mL).
The researchers noted that the results of this study “did not confirm the results of a previous retrospective study performed in patients with hemophilia A or B patients irrespective of severity that showed a difference in fTFPI levels between patients with hemophilia A and those with hemophilia B,” adding that they had no explanation for the difference between the results of these two studies.
Mean values of endogenous thrombin potential (ETP) and thrombin peak in platelet-poor plasma were significantly twice as high when fTFPI levels were &lt;9.4 compared with &gt;14.3 ng/mL (287.4 ± 111.1 vs 142.6 ± 69.1 nmol; P=.002 and 12.4 ± 5.6 vs. 5.1 ± 2.6 nmol; P=.001, respectively).
ETP values in platelet-rich plasma were also doubled in patients with fTFPI below 9.4 ng/mL compared with above 14.3 ng/mL; however, these differences were not statistically significant.
“Keeping in mind that platelets represent a major source of TFPI, the absence of a statistically significant difference in ETP and peak values in PRP according to fTFPI level measured in PPP may have reflected the fact that TFPI present within the platelets was not taken into account,” the researchers wrote.
Among those patients treated on demand, ETP and peak PRP were doubled when AJBR was ≤4.9; AJBR was halved in patients with low fTFPI level. Among those patients receiving prophylaxis, there was no association between TG parameters and fTFPI or AJBR.
Related: <a href="https://www.docwirenews.com/post/fidanacogene-elaparvovec-dzkt-approved-by-fda-for-hemophilia-b">Fidanacogene Elaparvovec-dzkt Approved by FDA for Hemophilia B</a>
Reference
Tardy-Poncet B, Montmartin A, Chambost H, et al. Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B. Haemophilia. 2024. doi: 10.1111/hae.15020.

Jordana Jampel

New Findings in Breast Cell Chromosomes May Challenge Early Disease Detection, Benefit Other Organ Disease Detection

Breast Cancer News

Rob Dillard

Assessing the Relationship Between Cardiac Implantable Electronic Devices, Tricuspid Regurgitation

AHA 2024

Emily Menendez

Tumor Treating Fields With Gemcitabine, Nab-Paclitaxel Improve OS in Advanced Pancreatic Cancer

Pancreatic Cancer

Latest News

Study Examines Factors Linked With Bleeding Risk in Severe Hemophilia

Hemophilia

Free tissue factor pathway inhibitor levels were associated with thrombin generation in patients with severe hemophilia. 

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe